Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
1. A method for the treatment of small cell lung cancer comprising administration to a patient in need thereof a combination of (i) an effective amount of a compound having the structure of:
or a pharmaceutically acceptable salt thereof; and (ii) etoposide.
2. The method of claim 1 , wherein the administration is oral administration.
3. The method of claim 1 , wherein the effective amount of the compound comprises about 1.5 mg/kg to about 10 mg/kg.
4. The method of claim 1 , wherein the compound is combined with at least one pharmaceutically acceptable excipient.
5. The method of claim 1 , wherein the salt of the compound is a besylate salt.
6. The method of claim 1 , wherein the compound is in the form of a tablet, pill, sachet, or capsule of hard or soft gelatin.
7. The method of claim 6 , wherein the compound is in the form of a tablet.
8. The method of claim 6 , wherein the compound is in the form of a pill.
9. The method of claim 6 , wherein the compound is in the form of a capsule.
10. The method of claim 1 , wherein the compound and the etoposide are administered in separate dosage forms.
11. The method of claim 1 , wherein the compound and the etoposide are administered concomittantly.
12. The method of claim 1 , wherein the etoposide is administered first.